VALSARTAN tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

VALSARTAN (UNII: 80M03YXJ7I) (VALSARTAN - UNII:80M03YXJ7I)

Inapatikana kutoka:

Northwind Pharmaceuticals

INN (Jina la Kimataifa):

VALSARTAN

Tungo:

VALSARTAN 160 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

1.1 Hypertension Valsartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee

Bidhaa muhtasari:

Valsartan is available as tablets containing valsartan, USP 40 mg, 80 mg, 160 mg, or 320 mg. All strengths are packaged in bottles as described below. 40 mg tablets are yellow colored, film-coated, oval-shaped tablets debossed with ' RX121' on one side and break line on the other side NDC 51660-140-03 Bottles of 10 NDC 51660-140-30 Bottles of 30 NDC 51660-140-05 Bottles of 500 80 mg tablets are yellowish brown colored, film-coated, oval-shaped tablets debossed with ' RX124' on one side and plain on the other side NDC 51660-141-03 Bottles of 10 NDC 51660-141-90 Bottles of 90 NDC 51660-141-05 Bottles of 500 160 mg tablets are pink colored, film-coated, oval-shaped tablets debossed with ' RX125' on one side and plain on the other side NDC 51660-142-03 Bottles of 10 NDC 51660-142-90 Bottles of 90 NDC 51660-142-05 Bottles of 500 320 mg tablets are brown colored, film-coated, oval-shaped tablets debossed with ' RX126' on one side and plain on the other side NDC 51660-143-03 Bottles of 10 NDC 51660-143-90 Bottles of 90 NDC 51660-143-05 Bottles of 500 Store at 20 o - 25o C (68o - 77o F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in tight container (USP).

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

VALSARTAN- VALSARTAN TABLET, FILM COATED
NORTHWIND PHARMACEUTICALS
----------
VALSARTAN 160MG
INDICATIONS AND USAGE
1.1 Hypertension
Valsartan tablets, USP are indicated for the treatment of
hypertension, to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal
cardiovascular events, primarily strokes
and myocardial infarctions. These benefits have been seen in
controlled trials of antihypertensive drugs
from a wide variety of pharmacologic classes including the class to
which valsartan principally
belongs. There are no controlled trials in hypertensive patients
demonstrating risk reduction with
valsartan tablets, USP.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking cessation,
exercise, and limited sodium intake. Many patients will require more
than one drug to achieve blood
pressure goals. For specific advice on goals and management, see
published guidelines, such as those
of the National High Blood Pressure Education Program’s Joint
National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different
mechanisms of action, have been shown in randomized controlled trials
to reduce cardiovascular
morbidity and mortality, and it can be concluded that it is blood
pressure reduction, and not some other
pharmacologic property of the drugs, that is largely responsible for
those benefits. The largest and
most consistent cardiovascular outcome benefit has been a reduction in
the risk of stroke, but reductions
in myocardial infarction and cardiovascular mortality also have been
seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk
increase per mmHg is greater at higher blood pressures, so that even
modest reductions of severe
hypertension can provide substantial benef